Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8341 to 8355 of 8398 results

  1. Learn more about NICE's new guideline on identifying and managing adrenal insufficiency

    Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen

  2. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.

  3. New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer

    Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..

  4. NICE enables groups and organisations to work together on their response to our online public consultations

    New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.

  5. Learn more about the proposed changes to our routing criteria for highly specialised technologies

    Home News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December 2024

  6. Additional evidence needed to assess histology-independent cancer drugs

    A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.

  7. NICE and NIHR: working together to produce research with impact

    Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.

  8. Dr Samantha Roberts starts work as NICE CEO today

    Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.

  9. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

  10. Patient safety and surgical innovation – why new isn't always better

    Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.

  11. Children and young people set to benefit from new treatment for peanut allergy

    Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.

  12. Putting user needs at the heart of an advisory service for AI and data-driven technologies

    Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.

  13. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  14. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  15. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.